Please assess the completion status of the following clinical trial:

Trial Title: Lenalidomide and Azacitidine in Treating Patients With Advanced Myelodysplastic Syndromes

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of myelodysplastic syndromes (MDS) meeting one of the following criteria:~  * French-American-British histological classification criteria~    * Refractory anemia with excess blasts (RAEB), defined as 5-19% myeloblasts in the bone marrow~      * Patients with 20% blasts are considered to have acute myeloid leukemia (per WHO classification system) and are therefore excluded in this study~   * Chronic myelomonocytic leukemia (CMML), defined as 10-19% myeloblasts in the bone marrow and/or 5-19% blasts in the blood~ * WHO histological classification criteria~    * RAEB-1, defined as 5-9% myeloblasts in the bone marrow~   * RAEB-2, defined as 10-19% myeloblasts in the bone marrow and/or 5-19% blasts in the blood~   * CMML-2, defined as 10-19% myeloblasts in the bone marrow and/or 5-19% blasts in the blood~ * International Prognostic Scoring System (IPSS) score of intermediate 2 (1.5-2.0 points based on karyotype, cytopenias, and bone marrow blast percentage) or high (≥ 2.5 points), in the setting of ≥ 5% myeloblasts~* Considered ineligible for bone marrow transplantation as first-line therapy~PATIENT CHARACTERISTICS:~* Life expectancy ≥ 3 months~* ECOG performance status 0-2~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective double-method contraception for 4 weeks before, during, and for 4 weeks after completion of study treatment~* No serious medical condition, laboratory abnormality, or psychiatric illness that, in the opinion of the treating physician, would preclude study participation or preclude giving informed consent~* No preexisting neurotoxicity or neuropathy ≥ grade 2~* No rash or prior hypersensitivity or allergic reaction ≥ grade 3 to thalidomide~* Creatinine ≤ 2.0 mg/dL~* AST and ALT ≤ 2.0 times upper limit of normal~* Bilirubin ≤ 2 mg/dL~* Platelet count ≥ 50,000/mm\^3~* Absolute neutrophil count ≥ 500/mm\^3~* No other malignancy within the past 3 years except curatively treated carcinoma in situ of the cervix or nonmelanoma skin cancer~* No history of thromboembolic event or other condition requiring use of anticoagulation with warfarin or low molecular-weight heparin~* No known or suspected hypersensitivity to azacitidine or mannitol~PRIOR CONCURRENT THERAPY:~* More than 28 days since prior and no other concurrent investigational agents for MDS~* More than 28 days since prior approved therapy for MDS~* More than 14 days since prior growth factors~* More than 28 days since prior and no concurrent supraphysiologic doses (equivalent to \> 10 mg/day of prednisone) of corticosteroids~* More than 12 months since prior radiotherapy, chemotherapy, or cytotoxic therapy for treatment of conditions other than MDS~* No prior lenalidomide or azacitidine~* No prior stem cell or bone marrow transplantation~* No concurrent androgens, epoetin alfa, or chemotherapy for MDS

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- Lenalidomide and Azacitidine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).